CytoDyn, Inc. (CYDY) Expects FDA Approval for PRO 140 in HIV by Q4 2019, $500M Revenue Forecast for 2020
PRO 140 has FDA fast track designation that allows accelerated approval The drug protects healthy cells from HIV infection by binding to CCR5 cellular co-receptor Market for PRO 140 as a single agent therapy projected at about $4 billion annually CYDY recently initiated its first cancer trial in triple negative breast cancer, targeting an unmet medical need CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV), expects to gain final FDA approval for its HIV treatment, PRO 140, by the fourth…